COMPLETED

Gender/Sex & CUD Remission

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.

Official Title

Gender and Sex Hormone Influences on Cannabis Use Disorder Remission

Quick Facts

Study Start:2021-11-15
Study Completion:2025-10-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04964739

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Willingness to participate in a research study (otherwise, will be referred to appropriate clinical services if seeking clinical care).
  2. 2. Meet current (within last 30 days) DSM-5 criteria for cannabis use disorder.
  3. 3. Submit a positive urine cannabinoid test during screening.
  4. 4. Interested in treatment for cannabis use disorder.
  1. 1. Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation.
  2. 2. The presence of any substance use disorder requiring a higher level of care.
  3. 3. Significant risk of homicide or suicide.
  4. 4. Pregnant, trying to become pregnant, or breastfeeding.

Contacts and Locations

Principal Investigator

Rachel L Tomko, PhD
PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Aimee L McRae-Clark, PharmD
PRINCIPAL_INVESTIGATOR
Medical University of South Carolina

Study Locations (Sites)

Medical University of South Carolina
Charleston, South Carolina, 29425
United States

Collaborators and Investigators

Sponsor: Medical University of South Carolina

  • Rachel L Tomko, PhD, PRINCIPAL_INVESTIGATOR, Medical University of South Carolina
  • Aimee L McRae-Clark, PharmD, PRINCIPAL_INVESTIGATOR, Medical University of South Carolina

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-15
Study Completion Date2025-10-27

Study Record Updates

Study Start Date2021-11-15
Study Completion Date2025-10-27

Terms related to this study

Additional Relevant MeSH Terms

  • Cannabis Use Disorder, Mild
  • Cannabis Use Disorder, Moderate
  • Cannabis Use Disorder, Severe